Blood test may spot liver cancer risk years early in cirrhosis patients
NCT ID NCT06778317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The goal is to catch liver cancer earlier and tailor screening to those who need it most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mSEPT9 blood test
What this could lead to
If successful, this blood test could help doctors identify cirrhosis patients at highest risk for liver cancer, allowing for earlier detection and personalized monitoring.
What could go wrong
This is an observational study, not a treatment trial. The test may not accurately predict cancer in all patients, and results may not change outcomes. Further studies would be needed to confirm its usefulness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Regional and University Hospital Center of Nancy
RECRUITINGVandœuvre-lès-Nancy, 54511, France
Contact Phone: •••-•••-•••• Email: •••••@•••••